Baxter price target raised to $54 from $52 at Barclays

Barclays analyst Matt Miksic raised the firm’s price target on Baxter to $54 from $52 and keeps an Overweight rating on the shares following the “solid” Q4 report. Baxter remains one of the “transformational stories” for 2024, on track to spin its lower-margin, slower-growing renal care business mid-year, the analyst tells investors in a research note. The firm says the company’s Q4 results and achievable 2024 outlook position the stock to outperform.